OGG1

Summary

OGG1 (8-oxoguanine DNA glycosylase, HGNC:8125) is a protein-coding gene on chromosome 3p25.3, encoding N-glycosylase/DNA lyase (O15527). DNA repair enzyme that incises DNA at 8-oxoG residues.

This gene encodes the enzyme responsible for the excision of 8-oxoguanine, a mutagenic base byproduct which occurs as a result of exposure to reactive oxygen. The action of this enzyme includes lyase activity for chain cleavage. Alternative splicing of the C-terminal region of this gene classifies splice variants into two major groups, type 1 and type 2, depending on the last exon of the sequence. Type 1 alternative splice variants end with exon 7 and type 2 end with exon 8. All variants share the N-terminal region in common, which contains a mitochondrial targeting signal that is essential for mitochondrial localization. Many alternative splice variants for this gene have been described, but the full-length nature for every variant has not been determined.

Source: NCBI Gene 4968 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nonpapillary renal cell carcinoma (Limited, GenCC)
• Clinical variants (ClinVar): 108 total
• Phenotypes (HPO): 2
• Druggable target: yes
• MANE Select transcript: NM_002542

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8125
Approved symbol	OGG1
Name	8-oxoguanine DNA glycosylase
Location	3p25.3
Locus type	gene with protein product
Status	Approved
Aliases	HMMH, HOGG1, OGH1, MUTM
Ensembl gene	ENSG00000114026
Ensembl biotype	protein_coding
OMIM	601982
Entrez	4968

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 12 protein_coding, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000302003, ENST00000302008, ENST00000302036, ENST00000339511, ENST00000344629, ENST00000352937, ENST00000383825, ENST00000383826, ENST00000416333, ENST00000425665, ENST00000426518, ENST00000429146, ENST00000432857, ENST00000436092, ENST00000441094, ENST00000449570, ENST00000602976, ENST00000707074

RefSeq mRNA: 13 — MANE Select: NM_002542 NM_001354648, NM_001354649, NM_001354650, NM_001354651, NM_001354652, NM_002542, NM_016819, NM_016820, NM_016821, NM_016826, NM_016827, NM_016828, NM_016829

CCDS: CCDS2576, CCDS2577, CCDS2578, CCDS2579, CCDS2580, CCDS2581, CCDS43046, CCDS46742

Canonical transcript exons

ENST00000344629 — 7 exons

Exon	Start	End
ENSE00001165146	9754704	9754885
ENSE00001644854	9751770	9751949
ENSE00001651617	9757061	9757407
ENSE00001669842	9750945	9751192
ENSE00001764469	9756767	9756816
ENSE00003477523	9756471	9756621
ENSE00003913150	9749952	9750423

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 92.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 19.0141 / max 136.0681, expressed in 1806 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
35227	9.8653	1735
35224	7.4665	1730
35225	0.8107	556
35228	0.6124	357
35229	0.1788	62
35226	0.0804	23

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	92.39	gold quality
ganglionic eminence	UBERON:0004023	91.96	gold quality
ventricular zone	UBERON:0003053	91.53	gold quality
oocyte	CL:0000023	91.08	gold quality
right ovary	UBERON:0002118	90.21	gold quality
metanephros cortex	UBERON:0010533	90.00	gold quality
left ovary	UBERON:0002119	89.84	gold quality
adult mammalian kidney	UBERON:0000082	89.49	gold quality
body of uterus	UBERON:0009853	89.35	gold quality
granulocyte	CL:0000094	89.05	gold quality
parotid gland	UBERON:0001831	89.04	gold quality
left uterine tube	UBERON:0001303	88.90	gold quality
right adrenal gland	UBERON:0001233	88.06	gold quality
lymph node	UBERON:0000029	88.05	gold quality
endocervix	UBERON:0000458	87.98	gold quality
right lobe of liver	UBERON:0001114	87.94	gold quality
right hemisphere of cerebellum	UBERON:0014890	87.74	gold quality
duodenum	UBERON:0002114	87.71	gold quality
cortex of kidney	UBERON:0001225	87.57	gold quality
right adrenal gland cortex	UBERON:0035827	87.52	gold quality
kidney	UBERON:0002113	87.50	gold quality
ovary	UBERON:0000992	87.46	gold quality
nephron tubule	UBERON:0001231	87.42	gold quality
putamen	UBERON:0001874	87.33	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.16	gold quality
cerebellar hemisphere	UBERON:0002245	87.15	gold quality
small intestine	UBERON:0002108	87.10	gold quality
cerebellar cortex	UBERON:0002129	87.10	gold quality
cingulate cortex	UBERON:0003027	87.09	gold quality
nerve	UBERON:0001021	87.07	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-100618	yes	377.46
E-ANND-3	yes	4.76

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): APEX1, DNMT1, NFE2L2, NFYA, PARP1, PGR, PROX1, SPI1, TFAP4, TP53, TP63

miRNA regulators (miRDB)

25 targeting OGG1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-609	99.82	64.26	505
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-182-3P	99.57	67.57	825
HSA-MIR-1252-3P	99.55	67.71	2862
HSA-MIR-548AV-3P	99.43	68.50	1721
HSA-MIR-103A-1-5P	99.39	67.78	1545
HSA-MIR-103A-2-5P	99.39	67.72	1577
HSA-MIR-544B	99.18	67.41	1632
HSA-MIR-3688-5P	99.12	69.67	1091
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-374B-3P	98.63	68.24	1360
HSA-MIR-3187-3P	97.38	65.80	904
HSA-MIR-509-3-5P	97.21	67.74	1517
HSA-MIR-509-5P	97.21	67.90	1512
HSA-MIR-3622A-3P	97.06	66.43	1000
HSA-MIR-4418	97.04	67.16	1372
HSA-MIR-3622B-3P	96.82	66.36	988
HSA-MIR-1266-3P	96.23	66.36	778
HSA-MIR-4509	96.19	65.80	900
HSA-MIR-217-3P	95.67	68.42	1000
HSA-MIR-5009-5P	94.82	63.89	775

Literature-anchored findings (GeneRIF, showing 40)

• OGG1 plays an important role in cell survival from radiation-induced damage (PMID:11827746)
• Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer’s disease brain. (PMID:11837743)
• crystal structure of native hOgg1 refined to 2.15 A resolution that reveals a number of highly significant conformational changes on association with DNA that are clearly required for substrate recognition and specificity (PMID:11902834)
• human OGG1 Cys/Cys genotype may confer a 2-fold increased risk of lung cancer (PMID:11927502)
• hOGG1 Ser(326)Cys polymorphism and modification by environmental factors of stomach cancer risk in Chinese (PMID:11992556)
• Human OGG1 undergoes serine phosphorylation and associates with the nuclear matrix and mitotic chromatin in vivo. (PMID:12034821)
• These results suggest that hOGG1 may play an important role in the repair of 8-OH-dG adducts in the aerodigestive tract and that the hOGG1 Ser326Cys polymorphism plays an important role in risk for smoking- and alcohol-related orolaryngeal cancer (PMID:12117782)
• may reduce oxygen mediated DNA damage in lung cells (PMID:12119232)
• the association of OGG1 Ser326Cys polymorphism was limited for the risk of lung adenocarcinoma (PMID:12164330)
• Inter-individual variation, seasonal variation and close correlation of OGG1 and ERCC1 mRNA levels in full blood (PMID:12189194)
• Data show that overexpression of 8-oxoguanine DNA glycosylase/apurinic lyase (OGG1) causes enhanced repair of and increased resistance to oxidative damage to mtDNA. (PMID:12244119)
• Aspartate-268 of OGG1 is a critical amino acid residue that plays a dual role, acting both as an N-terminal alpha-helix cap and as a critical residue for catalysis of both base excision and DNA strand cleavage by the enzyme. (PMID:12578369)
• we report the structure of a trapped catalytic intermediate in DNA repair by human 8-oxoguanine DNA glycosylase (PMID:12592398)
• Of the 18 cancer cell lines treated with oh(8)dG, 3 cell lines (H9, CEM-CM3, and Molt-4) were found to be committed to apoptosis, and all of these showed very low OGG1 activity and a marked increase in the concentration of oh(8)Gua in DNA. (PMID:12612057)
• study showed that 8-oxoguanine DNA glycosylase 1 is the only glycosylase that incises 8-oxoadenine, when base-paired with cytosine in mitochondria and nuclei, but a different enzyme incises 8-oxoadenine when base-paired with guanine in the nucleus (PMID:12644468)
• association of 8-oxoguanine glycosylase I polymorphism of Ser326Cys substitution with colon cancer risk and possible interaction with known environmental risk factors (PMID:12717837)
• hOGG1 expression change during differentiation of hematopoietic stem cells for adaptation to new environments (PMID:12754413)
• hOGG1 Ser326Cys polymorphism is unlikely to play a modifying role in individual susceptibility to breast cancer among Asian women. (PMID:12779082)
• OGG1 and MYH function as suppressors for G:C to T:A transversions by 8OHG but not by BPDE in human cells. (PMID:12807753)
• Significant age-dependent decrease in hOgg1 activity in lymphocytes. Significantly reduced activity was also shown in with Cysteine/Cysteine genotypes. The genders of the subjects were not shown to be associated. (PMID:12841596)
• hOGG1 protein turnover may be sensitive to intracellular redox changes (PMID:12899941)
• data presented support a model by which X-ray repair cross complementing protein 1 (XRCC1) will pass on the DNA intermediate from DNA glycosylase hOGG1 to the endonuclease APE1 (PMID:12933815)
• hOGG1 may have a role in the repair of 8-OH-dG adducts in prostate tissue and hOGG1 Ser326Cys polymorphism is associated with prostate cancer risk. (PMID:14634453)
• findings indicate that loss of hOGG1 expression may have a role in development or progression of clear cell renal cell carcinoma. (PMID:14663360)
• OGG1 is upregulated by NFYA following administration of DNA-alkylating agents (PMID:14688259)
• hOgg1 mutant proteins with a substitution of H270A or F319A are members of a new type of hOgg1 that is deficient in DNA glycosylase but proficient in AP lyase (PMID:14752045)
• hOGG1 polymorphism is associated with lung cancer risk and is linked to exposure to tobacco smoke (PMID:15077011)
• Finds no association between the hOGG1 (Ser326Cys) polymorphism and squamous cell carcinoma of the head and neck. (PMID:15184269)
• Because there is an increased incidence of lung and small intestine cancer in Myh(-/-)/Ogg1(-/-) mice, these findings support a causal role for unrepaired oxidized DNA bases in cancer development. (PMID:15231648)
• Single nucleotide polymorphism may play a role in the pathogenesis of lung cancer in this population, particularly among heavily exposed women. (PMID:15284179)
• OGG1 and Nei-like endonuclease (NEI1), DNA glycosylases which do not stably interact, stimulate 8-oxoguanine repair by a collaboration that is possible because of higher abasic (AP) site affinity and stronger AP lyase activity of NEI1 relative to OGG1. (PMID:15350146)
• OGG1 R154H may function as a low/moderate-penetrance modifier for colorectal cancer development (PMID:15449173)
• The mitochondrial beta-Ogg1 isoform lacks 8-oxoguanine DNA glycosylase activity. (PMID:15494448)
• hOGG1 Ser326Cys polymorphism is associated with gastric cancer (PMID:15596047)
• hOgg1 mainly operates as a monofunctional glycosylase under physiological concentrations of magnesium (PMID:15661661)
• human OGG1 is regulated by cadmium through suppression of Sp1 activity (PMID:15760895)
• Relocalization of hOGG1 to the nucleoli during the S-phase in cells expressing the hOGG1-Cys326 polymorphic variant. (PMID:15800211)
• X ray structure of human oxoG repair protein, 8-oxoguanine DNA glycosylase I (hOGG1), in the act of interrogating normal DNA (PMID:15800616)
• OGG1 targeted to mitochondria reduces the activation of caspase-9 (PMID:15811855)
• Higher expression levels of mitochondrial isoforms of OGG1 enzymes in the substantia nigra (SN) in cases of PD. Furthermore, Western blot analysis revealed high OGG1 levels in the SN of the patients with PD. (PMID:15841414)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	ogg1	ENSDARG00000060002
mus_musculus	Ogg1	ENSMUSG00000030271
rattus_norvegicus	Ogg1	ENSRNOG00000052140
drosophila_melanogaster	Ogg1	FBGN0027864

Protein

Protein identifiers

N-glycosylase/DNA lyase — O15527 (reviewed: O15527)

All UniProt accessions (15): O15527, A0A9L9PXU1, E5KPM5, E5KPM6, E5KPM7, E5KPM8, E5KPM9, E5KPN0, E5KPN1, F8WCZ9, H7BXZ1, H7BZM3, H7C0A1, H7C1D7, H7C1V7

UniProt curated annotations — full annotation on UniProt →

Function. DNA repair enzyme that incises DNA at 8-oxoG residues. Excises 7,8-dihydro-8-oxoguanine and 2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine (FAPY) from damaged DNA. Has a beta-lyase activity that nicks DNA 3’ to the lesion.

Subcellular location. Nucleus. Nucleoplasm. Nucleus speckle. Nucleus matrix Nucleus Mitochondrion.

Tissue specificity. Ubiquitous.

Disease relevance. Renal cell carcinoma (RCC) [MIM:144700] Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into clear cell renal carcinoma (non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma. Clear cell renal cell carcinoma is the most common subtype. The disease may be caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the type-1 OGG1 family.

Isoforms (8)

UniProt ID	Names	Canonical?
O15527-1	1A, Alpha	yes
O15527-2	1B
O15527-3	1C
O15527-4	2A, Beta
O15527-5	2B
O15527-6	2C
O15527-7	2D
O15527-8	2E

RefSeq proteins (13): NP_001341577, NP_001341578, NP_001341579, NP_001341580, NP_001341581, NP_002533, NP_058212, NP_058213, NP_058214, NP_058434, NP_058436, NP_058437, NP_058438 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003265	HhH-GPD_domain	Domain
IPR004577	Ogg1	Family
IPR011257	DNA_glycosylase	Homologous_superfamily
IPR012904	OGG_N	Domain
IPR023170	HhH_base_excis_C	Homologous_superfamily
IPR052054	Oxidative_DNA_repair_enzyme	Family

Pfam: PF00730, PF07934

Enzyme classification (BRENDA):

• EC 3.2.2.23 — DNA-formamidopyrimidine glycosylase (BRENDA: 13 organisms, 186 substrates, 18 inhibitors, 108 Km, 87 kcat entries)
• EC 4.2.99.18 — DNA-(apurinic or apyrimidinic site) lyase (BRENDA: 46 organisms, 543 substrates, 374 inhibitors, 166 Km, 138 kcat entries)

Substrate kinetics (BRENDA)

110 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
5’-CTCTCCCTTC-5,6-DIHYDROURACIL-CTCCTTTCCTCT-3'	—	13
13MER OLIGONUCLEOTIDE DUPLEX CONTAINING 8-OXOGUA	—	10
8-OXO-7,8-DIHYDROGUANINE:CYT OLIGODEOXYNUCLEOTID	—	9
DNA CONTAINING AN ABASIC SITE	100–413	9
5’-GACAAGCGCAG-(5R,6S)-2’-DEOXY-5,6-DIHYDROXYURI	—	8
DNA CONTAINING 8-HYDROXYGUANINE RESIDUES	—	7
DNA CONTAINING 5,6-DIHYDROURACIL	0.0006–0.0096	6
DNA CONTAINING 8-OXO-GUANINE RESIDUES	0.001–0.44	6
DNA CONTAINING 5-OH-C/A	—	6
5’-GACAAGCGCAG-(5S,6R)-2’-DEOXY-5,6-DIHYDROXYURI	—	5
DNA CONTAINING 5-OH-C/G	—	5
OLIGOMER WITH G/U PAIR	0.0001–0.0013	5
23MER OLIGONUCLEOTIDE DUPLEX CONTAINING 8-OXOGUA	—	4
DNA	—	4
DNA CONTAINING 2,6-DIAMINO-4-HYDROXY-5-FORMAMIDO	0.0018–0.0049	4

Catalyzed reactions (Rhea), 1 shown:

• 2’-deoxyribonucleotide-(2’-deoxyribose 5’-phosphate)-2’-deoxyribonucleotide-DNA = a 3’-end 2’-deoxyribonucleotide-(2,3-dehydro-2,3-deoxyribose 5’-phosphate)-DNA + a 5’-end 5’-phospho-2’-deoxyribonucleoside-DNA + H(+) (RHEA:66592)

UniProt features (72 total): helix 17, sequence variant 11, strand 11, binding site 9, splice variant 8, turn 5, mutagenesis site 3, sequence conflict 3, compositionally biased region 2, chain 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

47 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
8XWC	X-RAY DIFFRACTION	1.45
2XHI	X-RAY DIFFRACTION	1.55
5AN4	X-RAY DIFFRACTION	1.6
8XWU	X-RAY DIFFRACTION	1.68
8XXK	X-RAY DIFFRACTION	1.7
8XXG	X-RAY DIFFRACTION	1.82
9NZ8	X-RAY DIFFRACTION	1.85
1M3Q	X-RAY DIFFRACTION	1.9
6RLW	X-RAY DIFFRACTION	2
7AYY	X-RAY DIFFRACTION	2
9NZ9	X-RAY DIFFRACTION	2
1LWY	X-RAY DIFFRACTION	2.01
2NOH	X-RAY DIFFRACTION	2.01
1M3H	X-RAY DIFFRACTION	2.05
1EBM	X-RAY DIFFRACTION	2.1
1LWW	X-RAY DIFFRACTION	2.1
2NOB	X-RAY DIFFRACTION	2.1
1KO9	X-RAY DIFFRACTION	2.15
1N39	X-RAY DIFFRACTION	2.2
1N3A	X-RAY DIFFRACTION	2.2
2NOE	X-RAY DIFFRACTION	2.2
1LWV	X-RAY DIFFRACTION	2.3
3KTU	X-RAY DIFFRACTION	2.3
1HU0	X-RAY DIFFRACTION	2.35
2NOF	X-RAY DIFFRACTION	2.35
2NOI	X-RAY DIFFRACTION	2.35
6W0R	X-RAY DIFFRACTION	2.35
6W0M	X-RAY DIFFRACTION	2.37
6W13	X-RAY DIFFRACTION	2.38
1YQR	X-RAY DIFFRACTION	2.43

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O15527-F1	92.49	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 249 (schiff-base intermediate with dna)

Ligand- & substrate-binding residues (9): 270; 287; 315; 319; 149; 154; 204; 266; 268

Mutagenesis-validated functional residues (3):

Position	Phenotype
249	loss of activity.
268	no effect on activity.
268	decreases activity about 65-fold.

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-110328	Recognition and association of DNA glycosylase with site containing an affected pyrimidine
R-HSA-110329	Cleavage of the damaged pyrimidine
R-HSA-110330	Recognition and association of DNA glycosylase with site containing an affected purine
R-HSA-110331	Cleavage of the damaged purine
R-HSA-110357	Displacement of DNA glycosylase by APEX1
R-HSA-5649702	APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
R-HSA-9656255	Defective OGG1 Substrate Binding
R-HSA-9656256	Defective OGG1 Substrate Processing
R-HSA-9657050	Defective OGG1 Localization

MSigDB gene sets: 264 (showing top): GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, RNGTGGGC_UNKNOWN, MODULE_52, GOMF_ENDONUCLEASE_ACTIVITY, GOMF_NUCLEASE_ACTIVITY, GOBP_NEGATIVE_REGULATION_OF_DNA_REPAIR, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_CARBOHYDRATE_DERIVATIVE_CATABOLIC_PROCESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, AACYNNNNTTCCS_UNKNOWN, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, MODULE_16, KAUFFMANN_DNA_REPAIR_GENES, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, CAGCTG_AP4_Q5

GO Biological Process (14): base-excision repair (GO:0006284), base-excision repair, AP site formation (GO:0006285), nucleotide-excision repair (GO:0006289), regulation of DNA-templated transcription (GO:0006355), DNA damage response (GO:0006974), response to oxidative stress (GO:0006979), response to radiation (GO:0009314), cellular response to reactive oxygen species (GO:0034614), positive regulation of gene expression via chromosomal CpG island demethylation (GO:0044029), depurination (GO:0045007), depyrimidination (GO:0045008), positive regulation of transcription by RNA polymerase II (GO:0045944), negative regulation of double-strand break repair via single-strand annealing (GO:1901291), DNA repair (GO:0006281)

GO Molecular Function (16): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA binding (GO:0003677), damaged DNA binding (GO:0003684), endonuclease activity (GO:0004519), microtubule binding (GO:0008017), oxidized purine nucleobase lesion DNA N-glycosylase activity (GO:0008534), enzyme binding (GO:0019899), oxidized purine DNA binding (GO:0032357), 8-oxo-7,8-dihydroguanine DNA N-glycosylase activity (GO:0034039), class I DNA-(apurinic or apyrimidinic site) endonuclease activity (GO:0140078), catalytic activity (GO:0003824), protein binding (GO:0005515), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798), lyase activity (GO:0016829), DNA N-glycosylase activity (GO:0019104)

GO Cellular Component (8): nucleus (GO:0005634), nucleoplasm (GO:0005654), mitochondrion (GO:0005739), mitochondrial matrix (GO:0005759), cytosol (GO:0005829), nuclear matrix (GO:0016363), nuclear speck (GO:0016607), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Defective Base Excision Repair Associated with OGG1	3
Depyrimidination	2
Depurination	2
Resolution of Abasic Sites (AP sites)	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
DNA repair	2
DNA metabolic process	2
base-excision repair, AP site formation	2
DNA modification	2
catalytic activity	2
intracellular membrane-bounded organelle	2
nuclear lumen	2
cytoplasm	2
base-excision repair	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
cellular response to stress	1
response to stress	1
response to abiotic stimulus	1
response to reactive oxygen species	1
cellular response to oxidative stress	1
cellular response to oxygen-containing compound	1
transcription initiation-coupled chromatin remodeling	1
pyrimidine deoxyribonucleotide catabolic process	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
double-strand break repair via single-strand annealing	1
negative regulation of double-strand break repair	1
DNA damage response	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
nucleic acid binding	1
DNA binding	1
nuclease activity	1
tubulin binding	1
oxidized base lesion DNA N-glycosylase activity	1
protein binding	1
oxidized DNA binding	1
oxidized purine nucleobase lesion DNA N-glycosylase activity	1
DNA-(apurinic or apyrimidinic site) endonuclease activity	1
carbon-oxygen lyase activity	1
molecular_function	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

13 interactions, top by confidence:

A	B	Type	Score
APLNR	METTL15	psi-mi:“MI:0914”(association)	0.530
XPC	OGG1	psi-mi:“MI:0407”(direct interaction)	0.440
Ogg1	OGG1	psi-mi:“MI:0915”(physical association)	0.400
M		psi-mi:“MI:0914”(association)	0.350
NHLRC3	OGG1	psi-mi:“MI:0914”(association)	0.350
CD80	RIMOC1	psi-mi:“MI:0914”(association)	0.350
PTH2R	SPTLC2	psi-mi:“MI:0914”(association)	0.350
SLC2A12	NBAS	psi-mi:“MI:0914”(association)	0.350
OGG1	Hspd1	psi-mi:“MI:0403”(colocalization)	0.270
OGG1	SNRPF	psi-mi:“MI:0915”(physical association)	0.000
OGG1		psi-mi:“MI:0915”(physical association)	0.000
OGG1	CHGB	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (25): OGG1 (Affinity Capture-MS), SNRPF (Affinity Capture-MS), OGG1 (Affinity Capture-Western), CHD4 (Affinity Capture-Western), XRCC1 (Reconstituted Complex), XRCC1 (Two-hybrid), RAD1 (Affinity Capture-Western), RAD9A (Affinity Capture-Western), HUS1 (Affinity Capture-Western), OGG1 (Reconstituted Complex), OGG1 (Reconstituted Complex), OGG1 (Reconstituted Complex), CHGB (Two-hybrid), OGG1 (Affinity Capture-RNA), OGG1 (Biochemical Activity)

ESM2 similar proteins: A4FV98, A5D7B1, A5PK51, A6QLN9, A8MUP2, D3ZVU9, O15527, O35595, O75078, O95848, P57775, Q05B60, Q06643, Q14728, Q14CX5, Q1LZB9, Q27HK4, Q2T9T5, Q2TBS1, Q3UGX3, Q4R3I0, Q4V892, Q58CT4, Q5E9H2, Q5RCI5, Q5SUV1, Q5TM22, Q642A6, Q6IA17, Q6PCB0, Q6XQN6, Q862Z7, Q8N8L6, Q8R2R5, Q8R2Z5, Q8R366, Q8WUG5, Q95JH0, Q95JH2, Q969P0

Diamond homologs: O08760, O15527, O70249, P53397, Q9FNY7, Q9V3I8, O27397, F4JCQ3

SIGNOR signaling

6 interactions.

A	Effect	B	Mechanism
NFYA	“up-regulates quantity by expression”	OGG1	“transcriptional regulation”
TP53	“up-regulates quantity by expression”	OGG1	“transcriptional regulation”
NEDD4L	“down-regulates quantity by destabilization”	OGG1	ubiquitination
OGG1	up-regulates	DNA_repair
CUX2	“up-regulates activity”	OGG1	binding
OGG1	up-regulates	Base-excision_repair

Disease & clinical

Clinical variants and AI predictions

ClinVar

108 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	83
Likely benign	9
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

3634 predictions. Top by Δscore:

Variant	Effect	Δscore
3:9751760:T:A	acceptor_gain	1.0000
3:9751769:GGT:G	acceptor_gain	1.0000
3:9751817:A:AG	acceptor_gain	1.0000
3:9751817:ATCT:A	acceptor_gain	1.0000
3:9751818:T:G	acceptor_gain	1.0000
3:9751829:A:AG	acceptor_gain	1.0000
3:9751830:A:G	acceptor_gain	1.0000
3:9751832:A:AG	acceptor_gain	1.0000
3:9751833:A:G	acceptor_gain	1.0000
3:9751945:GGCTG:G	donor_gain	1.0000
3:9751946:GCTG:G	donor_gain	1.0000
3:9751946:GCTGG:G	donor_gain	1.0000
3:9751949:GGT:G	donor_loss	1.0000
3:9751950:G:GG	donor_gain	1.0000
3:9751951:T:G	donor_loss	1.0000
3:9751954:G:GG	donor_gain	1.0000
3:9754693:A:AG	acceptor_gain	1.0000
3:9754694:C:G	acceptor_gain	1.0000
3:9754702:A:AC	acceptor_loss	1.0000
3:9754702:A:AG	acceptor_gain	1.0000
3:9754702:AG:A	acceptor_gain	1.0000
3:9754702:AGG:A	acceptor_gain	1.0000
3:9754703:G:GG	acceptor_gain	1.0000
3:9754703:GG:G	acceptor_gain	1.0000
3:9754703:GGG:G	acceptor_gain	1.0000
3:9754703:GGGCC:G	acceptor_gain	1.0000
3:9754841:G:GT	donor_gain	1.0000
3:9754883:AAGG:A	donor_loss	1.0000
3:9754885:GGTGA:G	donor_loss	1.0000
3:9754886:G:GG	donor_gain	1.0000

AlphaMissense

2218 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:9750946:T:A	W47R	0.995
3:9750946:T:C	W47R	0.995
3:9751925:T:C	F181L	0.993
3:9751927:C:A	F181L	0.993
3:9751927:C:G	F181L	0.993
3:9750419:T:C	F45L	0.992
3:9750421:C:A	F45L	0.992
3:9750421:C:G	F45L	0.992
3:9750997:T:A	W64R	0.991
3:9750997:T:C	W64R	0.991
3:9750948:G:C	W47C	0.990
3:9750948:G:T	W47C	0.990
3:9754769:A:C	S211R	0.990
3:9754771:T:A	S211R	0.990
3:9754771:T:G	S211R	0.990
3:9756805:T:A	W313R	0.990
3:9756805:T:C	W313R	0.990
3:9757067:T:C	F319L	0.989
3:9757069:C:A	F319L	0.989
3:9757069:C:G	F319L	0.989
3:9751814:T:C	F144L	0.988
3:9751816:T:A	F144L	0.988
3:9751816:T:G	F144L	0.988
3:9754885:G:C	K249N	0.988
3:9754885:G:T	K249N	0.988
3:9754748:C:A	R204S	0.987
3:9751926:T:C	F181S	0.985
3:9756488:C:G	C255W	0.985
3:9751004:T:C	L66P	0.984
3:9754773:C:A	A212D	0.983

dbSNP variants (sampled 300 via entrez): RS1000011737 (3:9775214 G>A,C), RS1000111939 (3:9781199 G>A), RS1000142713 (3:9780889 A>G), RS1000255179 (3:9769578 C>T), RS1000349198 (3:9769287 C>A,T), RS1000523584 (3:9764563 C>T), RS1000716628 (3:9770583 G>A,C), RS1000819802 (3:9775363 T>C), RS1000976608 (3:9752051 C>G,T), RS1001226359 (3:9769638 T>G), RS1001233953 (3:9775854 G>T), RS1001240394 (3:9752352 A>T), RS1001263718 (3:9776202 C>G), RS1001436923 (3:9762597 T>G), RS1001442171 (3:9782206 C>G)

Disease associations

OMIM: gene MIM:601982 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
nonpapillary renal cell carcinoma	Limited	Autosomal dominant

Mondo (2): clear cell renal carcinoma (MONDO:0005005), nonpapillary renal cell carcinoma (MONDO:0007763)

Orphanet (1): Clear cell renal carcinoma (Orphanet:319276)

HPO phenotypes

2 total (2 of 2 shown, HPO-id order):

HPO	Term
HP:0003745	Sporadic
HP:0005584	Renal cell carcinoma

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3396944 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1052133	CAMK1, OGG1		0.00	0
rs293795	CAMK1, OGG1		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — DNA glycosylases

Binding affinities (BindingDB)

1 measured of 19 human assays (21 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
4-[4-(2-cyclohexyloxyethoxy)-2-oxo-3H-benzimidazol-1-yl]-N-(3-methoxy-4-methylphenyl)cyclohexane-1-carboxamide	IC50	118 nM	US-11970474: Substituted benzodiazoles and use thereof in therapy

ChEMBL bioactivities

35 potent at pChembl≥5 of 35 total, top 34 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.23	IC50	59	nM	CHEMBL5754134
6.66	IC50	220	nM	CHEMBL4441163
6.60	IC50	250	nM	CHEMBL6056196
6.57	IC50	270	nM	CHEMBL4470975
6.57	IC50	270	nM	CHEMBL5939244
6.54	IC50	290	nM	CHEMBL4568814
6.52	IC50	300	nM	CHEMBL4436904
6.48	IC50	330	nM	CHEMBL4437745
6.47	IC50	340	nM	CHEMBL4568814
6.46	IC50	350	nM	CHEMBL4441163
6.43	IC50	370	nM	CHEMBL4470975
6.41	IC50	390	nM	CHEMBL124433
6.38	IC50	420	nM	CHEMBL4437745
6.21	IC50	610	nM	CHEMBL4564367
6.20	IC50	630	nM	CHEMBL4564367
6.13	IC50	740	nM	CHEMBL4441163
6.11	EC50	780	nM	CHEMBL5429494
5.99	IC50	1030	nM	CHEMBL4441163
5.96	IC50	1100	nM	CHEMBL6001797
5.82	IC50	1530	nM	CHEMBL4466083
5.82	IC50	1500	nM	CHEMBL5815612
5.81	IC50	1560	nM	CHEMBL4437797
5.77	IC50	1700	nM	CHEMBL1514745
5.67	IC50	2130	nM	CHEMBL4593255
5.47	IC50	3380	nM	CHEMBL4584200
5.42	IC50	3780	nM	CHEMBL4579570
5.39	EC50	4100	nM	CHEMBL5402302
5.38	IC50	4150	nM	CHEMBL4568614
5.34	IC50	4560	nM	CHEMBL4445023
5.34	EC50	4600	nM	CHEMBL5411882
5.30	EC50	5000	nM	CHEMBL529145
5.29	EC50	5100	nM	CHEMBL5401642
5.14	IC50	7170	nM	CHEMBL3209772
5.00	IC50	1e+04	nM	CHEMBL4564367

PubChem BioAssay actives

25 with measured affinity, of 34 total; 20 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3,4-dichloro-1-benzothiophene-2-carbohydrazide	1801343: Gel-based Cleavage Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.2200	uM
3-chloro-N-[(Z)-(2-methylcyclohexylidene)amino]-1-benzothiophene-2-carboxamide	1801343: Gel-based Cleavage Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.2700	uM
N-(cyclohexylideneamino)-3-hydroxynaphthalene-2-carboxamide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.2900	uM
3-chloro-1-benzothiophene-2-carbohydrazide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.3000	uM
3-chloro-N-[(E)-(4-fluorophenyl)methylideneamino]-1-benzothiophene-2-carboxamide	1801343: Gel-based Cleavage Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.3300	uM
4-bromobenzohydrazide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.3900	uM
4-bromo-N-(cyclohexylideneamino)benzamide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	0.6100	uM
N-cyclohexyl-2-cyclopropylquinazolin-4-amine	2022484: Activation of OGG1 (unknown origin) by fluorescence-based assay	ec50	0.7800	uM
2-(4-chloro-3,5-dimethylphenoxy)acetohydrazide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	1.5300	uM
2-naphthalen-1-yloxyacetohydrazide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	1.5600	uM
3-bromo-N-[(Z)-hexan-2-ylideneamino]benzamide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	2.1300	uM
2-(3-chlorophenoxy)propanehydrazide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	3.3800	uM
3-bromo-N-[(Z)-hex-5-en-2-ylideneamino]benzamide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	3.7800	uM
(2S)-2-[(2-anilino-6-methylpyrimidin-4-yl)amino]-N-phenylpropanamide	2022484: Activation of OGG1 (unknown origin) by fluorescence-based assay	ec50	4.1000	uM
1-(4-methoxy-2,5-dimethylphenyl)sulfonyl-4-methyl-2-phenylimidazole	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	4.1500	uM
2,4-dichloro-N-[(1-propylpiperidin-4-ylidene)amino]benzamide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	4.5600	uM
2-[4-(4-imidazol-1-ylphenoxy)-5-methylpyrimidin-2-yl]-3,4,6,7,8,8a-hexahydro-1H-pyrrolo[1,2-a]pyrazine	2022484: Activation of OGG1 (unknown origin) by fluorescence-based assay	ec50	4.6000	uM
1-cyclohexyl-1-(2,4-dichlorophenyl)-2-imidazol-1-ylethanol	2022484: Activation of OGG1 (unknown origin) by fluorescence-based assay	ec50	5.0000	uM
2-(4-fluorophenyl)-N,1,7-trimethylpyrrolo[2,3-d]pyridazin-4-amine	2022484: Activation of OGG1 (unknown origin) by fluorescence-based assay	ec50	5.1000	uM
N-[(E)-1-(1,3-benzodioxol-5-yl)ethylideneamino]-3-hydroxynaphthalene-2-carboxamide	1801344: Fluorescence-based Assay from Article 10.1021/acschembio.5b00452: “Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).”	ic50	7.1700	uM

CTD chemical–gene interactions

123 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Arsenic	decreases reaction, affects cotreatment, decreases expression, increases abundance, affects expression (+1 more)	7
sodium arsenite	increases expression, decreases activity, affects cotreatment, decreases expression, increases abundance (+2 more)	5
Pesticides	increases response to substance, affects response to substance, affects cotreatment, decreases activity	5
Air Pollutants	increases methylation, affects response to substance, affects cotreatment, increases abundance, increases expression (+1 more)	4
Cadmium	affects activity, affects binding, decreases reaction, decreases expression, decreases activity (+1 more)	3
Hydrogen Peroxide	increases reaction, increases expression, increases response to substance	3
Ozone	increases abundance, affects expression, affects cotreatment, increases expression	3
Cadmium Chloride	affects cotreatment, increases expression, decreases expression, increases activity, increases methylation (+1 more)	3
4-biphenylamine	decreases expression, decreases reaction	2
bisphenol A	decreases reaction, decreases expression, increases methylation	2
sodium bichromate	increases response to substance, decreases expression	2
chromium hexavalent ion	affects expression, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
Decitabine	decreases reaction, increases expression, affects expression, affects reaction, decreases expression	2
Arsenic Trioxide	decreases expression, affects activity	2
Acetaminophen	increases expression	2
Glyphosate	affects activity, decreases expression, increases expression	2
Benzo(a)pyrene	increases methylation, decreases expression	2
Carmustine	decreases response to substance	2
Doxorubicin	increases expression, increases response to substance, decreases expression	2
Chlorpyrifos	increases expression, affects activity, affects expression, decreases expression	2
Estradiol	increases expression, increases response to substance, affects expression, affects reaction	2
Folic Acid	decreases expression, decreases reaction, increases expression	2
Thiotepa	decreases response to substance	2
Styrene	affects response to substance, increases expression	2
Vitamin K 3	increases response to substance, increases expression	2
Particulate Matter	increases abundance, increases methylation, decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
bisphenol F	affects cotreatment, decreases expression	1

ChEMBL screening assays

19 unique, capped per target: 18 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3398692	Binding	Inhibition of OGG1 (unknown origin) pre-incubated with compound for 10 mins followed by addition of 1,N6 ethenoadenine containing 32P-labeled duplex oligonucleotide substrates at 20 to 40 uM by gel-based excision activity assay	Naturally occurring polyphenol, morin hydrate, inhibits enzymatic activity of N-methylpurine DNA glycosylase, a DNA repair enzyme with various roles in human disease. — Bioorg Med Chem
CHEMBL5665450	Functional	Inhibition of OGG1 by quantifying inhibition of OGG1-mediated cleavage and dissociation of quenched duplex DNA oligonucleotides, measured as fluorescence at 594 nm. To generate a functional strand incision and increase turn-over this assay	Enzyme Inhibitor Single Concentration assay results for EUbOPEN Chemogenomics Library

Cellosaurus cell lines

6 cell lines: 6 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D1XY	Abcam A-549 OGG1 KO	Cancer cell line	Male
CVCL_D2C7	Abcam HCT 116 OGG1 KO	Cancer cell line	Male
CVCL_KT85	HeLa SilenciX Ogg1	Cancer cell line	Female
CVCL_TB61	HAP1 OGG1 (-) 1	Cancer cell line	Male
CVCL_TB62	HAP1 OGG1 (-) 2	Cancer cell line	Male
CVCL_TB63	HAP1 OGG1 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

499 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00414765	PHASE4	COMPLETED	Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
NCT00777504	PHASE4	UNKNOWN	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
NCT00930345	PHASE4	TERMINATED	Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
NCT01206764	PHASE4	COMPLETED	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
NCT01266837	PHASE4	COMPLETED	Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
NCT02056587	PHASE4	COMPLETED	Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment
NCT02338570	PHASE4	TERMINATED	Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)
NCT02596035	PHASE4	COMPLETED	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
NCT02982954	PHASE4	COMPLETED	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT05949424	PHASE4	UNKNOWN	OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT07028125	PHASE4	RECRUITING	Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma
NCT07405086	PHASE4	RECRUITING	Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
NCT01521715	PHASE4	COMPLETED	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
NCT02570789	PHASE4	TERMINATED	Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy
NCT00033904	PHASE3	COMPLETED	Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
NCT00126178	PHASE3	TERMINATED	Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer
NCT00291369	PHASE3	COMPLETED	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
NCT00326898	PHASE3	COMPLETED	Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
NCT00410124	PHASE3	COMPLETED	RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
NCT00474786	PHASE3	COMPLETED	Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib
NCT00478114	PHASE3	COMPLETED	Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
NCT00606632	PHASE3	COMPLETED	Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody
NCT00606866	PHASE3	COMPLETED	MRI Study of BAY 43-9006 in Metastatic Renal Cell Carcinoma
NCT00631371	PHASE3	COMPLETED	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
NCT00732914	PHASE3	COMPLETED	Sequential Study to Treat Renal Cell Carcinoma
NCT00869011	PHASE3	UNKNOWN	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib
NCT00930033	PHASE3	COMPLETED	Clinical Trial to Assess the Importance of Nephrectomy
NCT01030783	PHASE3	COMPLETED	A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
NCT01076010	PHASE3	COMPLETED	An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
NCT01198158	PHASE3	TERMINATED	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
NCT01223027	PHASE3	COMPLETED	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
NCT01224288	PHASE3	ACTIVE_NOT_RECRUITING	Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
NCT01235962	PHASE3	COMPLETED	A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)
NCT01265810	PHASE3	COMPLETED	Caphosol in Oral Mucositis Due to Targeted Therapy
NCT01265901	PHASE3	COMPLETED	IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01481870	PHASE3	UNKNOWN	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
NCT01575548	PHASE3	ACTIVE_NOT_RECRUITING	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
NCT01582672	PHASE3	TERMINATED	Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
NCT01613846	PHASE3	COMPLETED	Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II)
NCT01762592	PHASE3	WITHDRAWN	REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT